AU2015259346A1 - Dosage of dasotraline and method for treatment of ADHD - Google Patents

Dosage of dasotraline and method for treatment of ADHD Download PDF

Info

Publication number
AU2015259346A1
AU2015259346A1 AU2015259346A AU2015259346A AU2015259346A1 AU 2015259346 A1 AU2015259346 A1 AU 2015259346A1 AU 2015259346 A AU2015259346 A AU 2015259346A AU 2015259346 A AU2015259346 A AU 2015259346A AU 2015259346 A1 AU2015259346 A1 AU 2015259346A1
Authority
AU
Australia
Prior art keywords
dasotraline
adhd
treatment
methylphenidate
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015259346A
Other languages
English (en)
Inventor
Kenneth S. Koblan
Antony D. Loebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of AU2015259346A1 publication Critical patent/AU2015259346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015259346A 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of ADHD Abandoned AU2015259346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
US61/992,619 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (1)

Publication Number Publication Date
AU2015259346A1 true AU2015259346A1 (en) 2016-12-08

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015259346A Abandoned AU2015259346A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of ADHD

Country Status (10)

Country Link
US (1) US10076503B2 (https=)
EP (1) EP3143000A4 (https=)
JP (1) JP2017515849A (https=)
KR (1) KR20170005088A (https=)
CN (1) CN106660937A (https=)
AU (1) AU2015259346A1 (https=)
CA (1) CA2948839A1 (https=)
IL (1) IL248847A0 (https=)
MX (1) MX2016014768A (https=)
WO (1) WO2015175523A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
JP4610336B2 (ja) 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
NZ600107A (en) * 2009-12-04 2014-10-31 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and uses thereof

Also Published As

Publication number Publication date
IL248847A0 (en) 2017-01-31
EP3143000A1 (en) 2017-03-22
MX2016014768A (es) 2017-03-06
US10076503B2 (en) 2018-09-18
JP2017515849A (ja) 2017-06-15
US20170266134A1 (en) 2017-09-21
CA2948839A1 (en) 2015-11-19
WO2015175523A1 (en) 2015-11-19
KR20170005088A (ko) 2017-01-11
EP3143000A4 (en) 2017-12-13
CN106660937A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
CA3073996C (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
Biederman et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD
Labbate et al. Handbook of psychiatric drug therapy
JP2021098743A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
Biederman et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review
KR20170068480A (ko) 다발성 경화증의 치료를 위한 시포니모드 및 라퀴니모드를 포함하는 조합물
CN110167562A (zh) Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
Papakostas et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
US11324732B2 (en) Methods for the treatment of dyskinesia in cerebral palsy
JP2009515952A (ja) 制御放出性製剤のクエチアピン
US20170266133A1 (en) Methods and compositions of dasotraline for treatment of adhd
US10076503B2 (en) Dosage of dasotraline and method for treatment of ADHD
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
Silva et al. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder
JP2008525413A (ja) 双極性障害を治療するための単剤としてのサブコメリン、または、気分安定剤または抗躁病薬と併用されるサブコメリン
JP6301920B2 (ja) 疼痛治療薬
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Schmidt et al. P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia
KR20260033016A (ko) 병리적 무관심의 치료 및/또는 예방에 사용하기 위한 3-(2,3-디플루오로페녹시)아제티딘 또는 이의 약제학적으로 허용되는 염
Willis et al. P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic
Stanković et al. Sulpiride Augmentation in refractory depression

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted